SymbolMGX
NameMETAGENOMI, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address5959 HORTON STREET,7TH FLOOR, EMERYVILLE, California, 94608, United States
Telephone+1 510 871-4880
Fax
Email
Websitehttps://metagenomi.co
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001785279
Description

At Metageno-mi, we are cre-at-ing poten-tial-ly cura-tive ther-a-peu-tics using our metage--nomics-pow-ered genome edit-ing toolbox.We believe tools with capa-bil-i-ties that go beyond the cur-rent tech-nol-o-gy land-scape will be required in order to reach the full ther-a-peu-tic poten-tial of genome edit-ing. By har-ness-ing the pow-er of metage-nomics, the study of genomes recov-ered from uncul-ti-vat-ed organ-isms in the nat-ur-al envi-ron-ment, we are dis-cov-er-ing and devel-op-ing a suite of nov-el genome edit-ing tools with the poten-tial to make any desired ther-a-peu-tic gene edit, any-where in the human genome.

Additional info from NASDAQ:
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, integration and correction.

Additional info from NASDAQ:
At Metageno-mi, we are cre-at-ing poten-tial-ly cura-tive ther-a-peu-tics using our metage--nomics-pow-ered genome edit-ing toolbox.We believe tools with capa-bil-i-ties that go beyond the cur-rent tech-nol-o-gy land-scape will be required in order to reach the full ther-a-peu-tic poten-tial of genome edit-ing. By har-ness-ing the pow-er of metage-nomics, the study of genomes recov-ered from uncul-ti-vat-ed organ-isms in the nat-ur-al envi-ron-ment, we are dis-cov-er-ing and devel-op-ing a suite of nov-el genome edit-ing tools with the poten-tial to make any desired ther-a-peu-tic gene edit, any-where in the human genome.

2026-05-11 20:09

(30% Negative) METAGENOMI, INC. (MGX) Reports Q2 2026 Financial Results

Read more
2026-05-11 20:05

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Read more
2026-04-27 17:59

New Form ARS - Metagenomi Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182345 <b>Size:</b> 4 MB

Read more
2026-04-27 17:58

New Form DEFA14A - Metagenomi Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182339 <b>Size:</b> 1 MB

Read more
2026-04-27 17:55

New Form DEF 14A - Metagenomi Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182325 <b>Size:</b> 2 MB

Read more
2026-04-16 11:00

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Read more
2026-04-03 18:11

Irish Jian 🟢 acquired 322.0K shares (1 derivative) of Metagenomi Therapeutics, Inc. (MGX) at $1.34 Transaction Date: Apr 01, 2026 | Filing ID: 141946

Read more
2026-04-03 18:00

Wein Matthew 🟢 acquired 79.0K shares (1 derivative) of Metagenomi Therapeutics, Inc. (MGX) at $1.34 Transaction Date: Apr 01, 2026 | Filing ID: 141914

Read more
2026-04-03 17:40

Wapnick Pamela 🟢 acquired 168.0K shares (1 derivative) of Metagenomi Therapeutics, Inc. (MGX) at $1.34 Transaction Date: Apr 01, 2026 | Filing ID: 141867

Read more
2026-03-05 21:05

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Read more